Compare SKYX & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYX | NBP |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.5M | 205.9M |
| IPO Year | 2014 | 2019 |
| Metric | SKYX | NBP |
|---|---|---|
| Price | $1.04 | $1.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $4.00 | ★ $9.00 |
| AVG Volume (30 Days) | 538.4K | ★ 638.2K |
| Earning Date | 11-11-2026 | 08-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,700,948.00 | N/A |
| Revenue This Year | $16.10 | N/A |
| Revenue Next Year | $27.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.78 | N/A |
| 52 Week Low | $0.95 | $1.26 |
| 52 Week High | $3.29 | $5.19 |
| Indicator | SKYX | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 33.51 | 28.73 |
| Support Level | $0.98 | N/A |
| Resistance Level | $1.12 | $1.44 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 2.33 | 16.67 |
SKYX Platforms Corp operates in the business of developing proprietary technology that enables a quick and safe installation of electrical fixtures, such as light fixtures and ceiling fans. Its technology consists of a weight-bearing, fixable socket and a revolving plug for conducting electric power and supporting an electrical appliance attached to a wall or ceiling. The socket is comprised of a nonconductive body that houses conductive rings connectable to an electric power supply through terminals in its side exterior. The plug is also comprised of a nonconductive body that houses corresponding conductive rings, attaches to the socket via a male post, and is capable of feeding electric power to an appliance. It generates its income from lighting and heating products sold in the USA.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.